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Background: Opioid use rates prior to knee arthroplasty (KA) among people who catastro-
phize about their pain are unknown. We determined prevalence of opioid use and compared 
patterns of preoperative opioid use and oral morphine equivalent (OME), a measure of daily 
opioid dose, across varied geographic sites. We also determined which baseline variables were 
associated with opioid use and OME.
Patients and methods: Preoperative opioid use data described type of opioid, dosage, and 
frequency among 397 patients scheduled for KA. Demographic, knee-related pain, and psy-
chological distress dimensions were examined to identify variables associated with opioid use 
and opioid dose (OME). Opioid use prevalence and OME were compared across the four sites. 
A three-level censored regression determined variables associated with opioid use and OME.
Results: The overall opioid use prevalence was 31.7% (95% confidence interval [CI] = 27.0, 
36.3) and varied across sites from 15.9% (95% CI = 9.0, 22.8) to 51.2% (95% CI = 40.5, 61.9). 
After adjustment, patients using opioids were more likely to be younger, African American, and 
have higher self-efficacy and comorbidity scores (P < 0.05). The only variable independently 
associated with OME was lower depressive symptoms (P < 0.05).
Conclusion: People who catastrophized prior to KA did not demonstrate increased preoperative 
opioid use based on current evidence, but variation in the prevalence of opioid use across study 
sites was substantial. Variables associated with opioid use were non-modifiable demographic 
and comorbidity variables.
Keywords: pain, catastrophizing, opioid, knee, arthroplasty
Introduction
Persistent opioid use by people with knee arthroplasty (KA) is a substantial problem 
that has received recent attention.1–4 Patients undergoing KA, for example, have the 
highest rate of postoperative opioid use among several of the more common major 
surgical procedures.2 The Centers for Disease Control and Prevention recently pro-
posed guidelines for treating people with chronic pain,5 and the American Academy of 
Orthopaedic Surgeons (AAOS) has endorsed these recommendations.6 Chief among 
the guideline recommendations are that opioids should be used only when benefits in 
pain relief and function are expected to outweigh risks. Opioid-related risks in people 
with chronic pain have been highly publicized and include addiction, overdose, and 
death.7 Moreover, a recent systematic review8 and randomized clinical trial9 of opioids 
versus nonsteroidal anti-inflammatory drugs (NSAIDs) for people with chronic knee 
pain found that NSAIDs provided comparable pain relief to opioids.
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Among patients with knee osteoarthritis (OA) undergo-
ing KA, the most powerful predictor of persistent opioid 
use is preoperative opioid use.3,10 An additional important 
predictor of persistent opioid use in people with chronic 
musculoskeletal pain11,12 is pain catastrophizing.3,13 Patients 
who catastrophize tend to ruminate about their pain, feel 
helpless by pain and magnify effects of pain on daily life.14,15
We recently recruited a multisite sample of patients sched-
uled for KA surgery who also had moderate to high levels of 
pain catastrophizing for a four-site randomized clinical trial 
of a Knee Arthroplasty Pain Coping Skills Training (KAST-
Pain) trial.16 The overall purpose of the current investigation 
was to characterize the prevalence and type of preoperative 
opioid use in this unique KASTPain patient sample. Spe-
cifically, we estimated site-specific prevalence of opioid use 
among four clinical sites, the opioid morphine equivalent 
(OME) and variables associated with opioid use and OME. 
Because of the recent focus on the opioid use epidemic and 
importantly, methods to identify people at risk for opioid 
use, we focused on the rate of opioid use preoperatively, 
predictors of preoperative opioid use, and variation in the 
rate of opioid use across sites. Clinicians will likely benefit 
from knowing variables that associate with increased risk of 
preoperative opioid use and the extent to which opioid use 
varies across clinical sites. We hypothesized that the four 
sites would demonstrate varied opioid use but that overall, 
we would find a higher prevalence of opioid use as compared 
to the US literature-based historical control estimates of 
25%–30%3,17,18 because we studied individuals with moder-
ate to high pain catastrophizing. We also hypothesized that 
a variety of modifiable, patient-level health variables would 
be associated with preoperative opioid use and dose after 
adjustment for non-modifiable variables.
Patients and methods
The study sample was taken from a three-arm randomized 
clinical trial with 1-year follow-up that examined effects 
of physical therapist-delivered pain coping skills relative 
to arthritis education or usual care for patients with at least 
moderate pain catastrophizing and scheduled for KA (the 
KASTPain study). The protocol for the trial has been pub-
lished.16 Data collected were approved by the institutional 
review board (IRB) of the four participating sites (Virginia 
Commonwealth University, Duke University, Wake Forest 
University, and New York University). All subjects read and 
signed an IRB-approved consent form. While data were col-
lected during a preoperative visit and at 2, 6, and 12 months 
post surgery, the focus of the current study was the baseline 
preoperative data.
Study sample
Participants had consented to KA prior to being screened for 
KASTPain. To be eligible, all participants were 45 years or 
older, passed a cognitive screen,19 had a diagnosis of knee 
OA, and were scheduled for KA between 1 and 8 weeks 
following consent. Additionally, participants scored ≥16 on 
the Pain Catastrophizing Scale (PCS) and ≥5 on the Western 
Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) Pain scale. Scores of ≥16 on the PCS indicate 
at least moderate pain catastrophizing, while scores of ≥5 
on the WOMAC Pain scale indicate at least minor function 
limiting pain. Exclusion criteria were revision or bilateral KA, 
inflammatory arthritis, fracture, malignancy or infection, or 
plans to undergo additional arthroplasty within 6 months of 
the index surgery.
The clinical trial was pragmatic by design in that we 
did not control the modes of analgesia, operative and phar-
macologic pain management practices, or the perioperative 
surgical care at the participating sites. Controls would have 
artificially restricted variation in perioperative care and 
reduced generalizability of trial findings.
Outcomes of interest – baseline opioid 
use and dose
Following consent, study coordinators asked each participant 
to identify all medications taken specifically for knee pain 
from an extensive medication list. We focused on opioids 
specifically taken for knee pain because patients undergo-
ing KA arthroplasty may be prescribed opioids for pain 
in other regions and the KA evidence has not specifically 
determined extent of opioid use for knee pain, the target of 
the KA intervention.3 Participants were categorized as either 
using or not using opioids. Evidence supports the validity 
of self-reported opioid use (yes or no) during in-person 
interviews.20,21 In addition to the type of opioid, participants 
indicated dosage and daily frequency of use for each opioid. 
Because patients may not accurately recall their opioid dos-
age, we reviewed the electronic medical record and recorded 
the medical record-based opioid dosage obtained from each 
participating site. Additionally, because some patients only 
take opioids as needed, we relied on participants’ self-report 
of frequency as compared to prescribed frequencies docu-
mented in the medical record. We used self-reported opioid 
type, medical record-based dosage, and self-reported daily 
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frequency to calculate the OME, reported in milligrams per 
day, as a measure of daily dose of opioid use.22 The OME 
is calculated by multiplying dosage by daily frequency by a 
conversion factor for each opioid based on opioid strength.22
Additional baseline variables
The WOMAC Pain, Function, and Stiffness scales were used 
to quantify the extent of function limiting pain and difficulty 
with activity. WOMAC has strong psychometric properties 
for people with KA.23–25 Bodily pain location and severity 
were measured with a validated questionnaire.26 The bodily 
pain questionnaire asked the patient to identify which of 16 
body regions had been painful for at least the prior 3 months. 
The previously validated Generalized Anxiety Disorder-7 
(GAD-7) scale27 and the Patient Health Questionnaire-8 
(PHQ-8) scale28 were used to quantify extent of anxiety and 
depressive symptoms, respectively. The eight-item Arthritis 
Self-Efficacy Scale is a validated measure of participants’ 
beliefs in their abilities to control symptoms and functional 
challenges associated with arthritis.29 Comorbidity was quan-
tified using a previously validated and modified Charlson 
Comorbidity Index.30 The PCS was used to measure pain 
catastrophizing.31 A substantial literature supports the psy-
chometric properties of the PCS31,32 and the prognostic role 
of PCS scores in predicting poor outcome following KA.33–35 
We conceptualized pain catastrophizing as minor, moderate, 
or severe based on approximate tertile distributions for the 
scale. Pain catastrophizing was considered as minor for scores 
of 0–15 (not included in this study), moderate for scores of 
16–29, and severe for scores of 30–52. For all scales, with one 
exception (i.e., Arthritis Self-Efficacy Scale), higher scores 
equated to worse results. Demographic measures included 
age, sex, race (African American or other), body mass index 
(BMI; kg/m2), and current smoking status (Table 1 presents 
descriptive data and score ranges for each scale).
Data analysis
Descriptive statistics were used to summarize all baseline vari-
ables, while independent sample t-tests were used to compare 
continuous measures for opioid and non-opioid users. The 
chi-square statistic was applied to categorical variables. We 
used three-level, two-part regression analysis with a random 
intercept term to predict opioid use (yes or no) and oral mor-
phine equivalent (OME).The analysis accounted for patients 
nested within surgeons and surgeons nested within site as 
well as the patients who did not report opioid use. Multilevel 
modeling accounts for differences in outcomes at both the 
surgeon and site levels so that any remaining associations 
cannot be  attributed to surgeon or site but rather the predictor 
variables of interest. Two regression equations were estimated 
from the set of predictors based on prior evidence linking 
these predictors with opioid use.3,17,36 In the first equation, 
the outcome was binary (opioid user versus nonuser). In the 
second equation, the magnitude of OME was estimated from 
the predictors among those who had nonzero OME values. 
For the OME equation, outcome was censored below an OME 
score of 1 because many patients did not take opioids, leading 
to an accumulation of zeros in the outcome distribution. The 
two-step procedure described by Kapitula was used to estimate 
all model parameters.37 All analyses were conducted using 
SAS software, Version 9.4 of the SAS System for Windows, 
Copyright ©2016 (SAS Institute Inc., Cary, NC, USA).
Results
A total of 397 participants from four sites provided consent, 
and of these patients, 18 had their surgery canceled, while 
379 underwent KA. Of these patients, 362 had total KA, 
Table 1 Preoperative comparisons between patients taking 
opioids for knee pain and patients not taking opioids (total n = 
379)
Patient characteristics Opioid use P value
Yes (n = 
120)
No (n = 
259)
Demographics
Age (years) 60.84 (7.63) 64.34 (7.99) <0.001
Female (yes) 32.8% 29.4% 0.50
BMI (kg/m2) 33.27 (6.11) 31.69 (6.19) 0.022
African American (yes) 46.3% 23.7% <0.001
Current smoker (yes) 18.3% 8.1% 0.004
Total KA (yes) 96.7% 95% 0.461
Knee-related health
WOMAC Pain (0–20) 12.42 (3.41) 10.89 (3.25) <0.001
WOMAC Function (0–68) 39.68 (11.29) 35.85 (11.49) 0.003
WOMAC Stiffness (0–8) 5.12 (1.82) 4.74 (1.87) 0.07
Knee pain duration (years) 11.43 (11.05) 10.06 (10.75) 0.256
Overall health
Bodily pain score (0–16) 6.83 (4.43) 5.02 (3.72) <0.001
Comorbidity score (0–45) 10.43 (4.60) 7.82 (3.54) <0.001
Psychological health
GAD-7 (0–21) 6.66 (5.34) 4.71 (4.60) <0.001
PHQ-8 depressive 
symptoms (0–24)
7.19 (5.32) 5.25 (4.56) <0.001
PCS pain catastrophizing 
(0–52)
31.10 (9.54) 29.29 (9.12) 0.078
Self-efficacy (8–80) 48.40 (18.30) 49.81 (17.63) 0.476
Notes: Data are presented as mean (SD) or percent. Independent sample t-tests 
were conducted on continuous variables and c2 tests were applied to categorical 
variables.
Abbreviations: BMI, body mass index; KA, knee arthroplasty; WOMAC, 
Western Ontario and McMaster Universities Osteoarthritis Index; GAD-7, 
Generalized Anxiety Disorder-7; PHQ-8, Patient Health Questionnaire-8; PCS, Pain 
Catastrophizing Scale.
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while 17 underwent unicompartmental KA. The average 
age of participants was 63.2 years; 35.4% self-reported as 
African American and 66.8% were females. Self-reported 
knee pain duration ranged from a minimum of 5 months to 
a maximum of 58 years. Because of substantially skewed 
pain duration data, the median pain duration was 6 years 
(first quartile = 3 years, third quartile = 15 years). This dura-
tion of knee pain is typical of people undergoing KA and is 
consistent with definitions of chronic pain (>3 months).38 
People using opioids for knee pain were younger (P < 0.001), 
more likely to be African American (P < 0.001), and reported 
worse WOMAC Pain score (P < 0.001) and Function score 
(P = 0.003), greater comorbidity scores (P < 0.001), more 
bodily pain areas (P < 0.001), and worse anxiety and depres-
sive symptoms (P < 0.001). The characteristics of those 
using opioids and those not using opioids are summarized 
in Table 1. The correlation matrix of psychological distress, 
WOMAC, comorbidity, and bodily pain site measures is given 
in Table 2. As expected, the association between WOMAC 
Pain and Function measures was high (r = 0.72) as was 
the association between anxiety and depressive symptoms 
(r = 0.70). The remaining associations were in the low to 
moderate range. A variety of different types, dosages, and 
frequencies of daily opioid use were reported, and these are 
summarized in Table 3.
Prevalence of preoperative opioid use 
and opioid dose across the four sites
The overall proportion of opioid use was 31.7% (95% confi-
dence interval [CI] = 27.0, 36.3). The prevalence of opioid use 
among those with unicompartmental versus total KA was not 
significantly different (c2 = 0.54, P = 0.47). The proportion 
of opioid users ranged from 15.9% (95% CI = 9.0, 22.8) for 
Site 4 to 51.2% (95% CI = 40.5, 61.9) for Site 1 (Figure 1). 
Of the 120 patients who self-reported opioid use, OME data 
were available for 110 patients. Because of skewed OME data, 
we report medians. For the entire sample, median OME was 
22.5 mg/day. The median OME potency per site ranged from 
15 to 30 mg/day (Table 3).
Baseline variables associated with opioid 
use
After accounting for patients nested within surgeon and 
surgeons nested within site, younger age (P = 0.01), Afri-
can American race (P = 0.02), higher self-efficacy (P = 
0.02), and higher comorbidity score (P < 0.001) increased 
the probability of opioid use (Table 4). Odds ratios were 
reported such that, for example, for every point increase in 
the comorbidity score, odds of using an opioid increased, 
on average, by 14.5%. The parameter estimate for age was 
coded as negative, which indicates that, on average, for 
every year increase in age, opioid use decreased by 4.5%. 
Psychological distress variables, number of bodily pain sites, 
and WOMAC Pain scores were not associated (P > 0.05) 
with opioid use after adjusting for the other variables in the 
model (Table 4).
Table 2 Correlation matrix for the psychological health, comorbidity, WOMAC, and bodily pain site scoresa
PCS GAD-7 PHQ-8 Self-efficacy Comorbidity WOMAC Pain WOMAC 
Stiffness
WOMAC 
Function
GAD-7 0.307
PHQ-8 0.266 0.702
Self-efficacy –0.208 -0.341 -0.372
Comorbidity 0.182 0.314 0.355 –0.236
WOMAC Pain 0.429 0.256 0.292 –0.252 0.284
WOMAC Stiffness 0.159 0.158 0.213 –0.210 0.183 0.451
WOMAC Function 0.393 0.283 0.351 –0.260 0.315 0.724 0.510
Bodily pain 0.162 0.340 0.335 –0.220 0.408 0.340 0.291 0.326
Note: aAll coefficients are significantly different from 0 at the P < 0.01 level.
Abbreviations: WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; PCS, Pain Catastrophizing Scale; GAD-7, Generalized Anxiety Disorder-7; 
PHQ-8, Patient Health Questionnaire-8.
Table 3 Summary of opioid type, dosage, and frequency for 120 
patients taking opioids
Category n (%) Median  
milligram  
dosage  
(range)
Median  
daily  
frequency  
(range)
Codeine with acetaminophen 5 (4.17) 30 (5–30) 1 (1–4)
Hydrocodone 34 (28.33) 7.5 (1–30) 2 (1–6)
Morphine 3 (2.5) 15 (5–50) 3 (2–3)
Oxycodone 44 (36.67) 5 (5–50) 2 (1–4)
Tramadol 48 (40.0) 50 (10–100) 2 (1–6)
Methadone 3 (2.5) 10 (10–20) 3 (2–4)
Othersa 3 (2.5) – –
Note: aHydromorphone, tapentadol, and fentanyl patch.
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Figure 1 Proportion (with 95% CIs) of patients at each of four sites who reported taking opioids for their knee pain prior to surgery.
Abbreviation: CI, confidence interval.
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Table 4 Results of regression models of variables associated with either opioid use or OME
Model and variables Regression 
parameter
SE t value P Odds ratio (CI)
Opioid use (yes or no)
Intercept –1.630 1.582 –1.03 0.379
Pain catastrophizing (PCS) –0.016 0.016 –0.99 0.324 0.985 (0.954, 1.016)
Depressive symptoms (PHQ-8) 0.015 0.037 0.42 0.672 1.016 (0.954, 1.092)
Self-efficacy scale 0.020 0.008 2.43 0.016 1.020 (1.004, 1.037)
Bodily pain sites 0.022 0.036 0.61 0.543 1.022 (0.953, 1.096)
Anxiety symptoms (GAD-7) 0.037 0.037 0.97 0.332 1.037 (0.963, 1.096)
Comorbidity score (modified Charlson) 0.136 0.036 3.81 <0.001 1.145 (1.068, 1.228)
Knee pain (WOMAC Pain) 0.077 0.045 1.72 0.086 1.080 (0.989, 1.180)
Age (years) –0.046 0.018 –2.58 0.010 0.955 (0.922, 0.989)
Race (African American) 0.621 0.275 2.26 0.024 1.862 (1.085, 3.195)
BMI 0.012 0.022 0.56 0.576 1.012 (0.970, 1.057)
Sex (female) 0.072 0.279 0.26 0.798 1.074 (0.620, 1.861)
OME
Intercept 51.583 59.078 0.87 0.447
Pain catastrophizing (PCS) 0.005 0.528 0.01 0.993
Depressive symptoms (PHQ-8) –2.635 1.190 –2.22 0.030
Self-efficacy –0.151 0.280 –0.54 0.590
Bodily pain sites 1.569 1.039 1.51 0.135
Anxiety symptoms (GAD-7) 0.735 1227 0.60 0.552
Comorbidity score –0.452 1.233 –0.37 0.715
Knee pain (WOMAC Pain) 1.419 1.450 0.98 0.331
Age (years) –0.302 0.615 –0.49 0.625
Race (African American) 3.518 8.980 0.39 0.696
BMI 0.067 0.751 0.09 0.929
Sex (female) –4.430 9.435 –0.47 0.640
Abbreviations: OME, oral morphine equivalent; SE, standard error; CI, confidence interval; PCS, Pain Catastrophizing Scale; PHQ-8, Patient Health Questionnaire-8; 
GAD-7, Generalized Anxiety Disorder-7; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; BMI, body mass index.
Journal of Pain Research  2018:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1554
Riddle et al
Baseline variables associated with OME
After accounting for patients nested within surgeon and 
surgeons nested within site, the only variable associated 
with OME was lower depressive symptoms (P = 0.030). For 
every point increase in the PHQ-8 depressive symptoms 
score, OME decreased by 2.6 mg after adjusting for all other 
variables in the model.
Discussion
Several guidelines for the treatment of knee OA exist 
including those developed by the AAOS39 and the American 
College of Rheumatology (ACR).40 These guidelines do not 
recommend the routine use of opioids for the treatment of 
knee OA, and the ACR recommends that they should be used 
only for patients deemed not to be surgical candidates. In 
addition, opioids have been shown to be no more effective 
than NSAIDs for the treatment of knee OA.8 Highlighting the 
potential overuse of these medications, the Surgeon General 
sent a letter in 2016 to every physician in America calling 
for clinicians to receive education on how to treat pain safely 
and effectively to positively impact the opioid epidemic.41
Consensus-based recommendations for the use of opioids 
are generally vague. The lack of clarity of definitions for 
whom opioids should be prescribed combined with a lack 
of clinician training likely leads to substantial variation in 
opioid prescribing not only for pain associated with knee 
OA as we found, but also for many other pain conditions.42 
For patients scheduled for KA, an opioid use rate of ~30% 
has been consistently reported and was supported in our 
study. Whether an opioid use rate of 30% represents overuse, 
underuse, or appropriate use cannot be determined from our 
study or from current evidence. However, the substantial 
variation across the four sites with opioid use rates ranging 
from 15.9% to 51.2% suggests that there is likely inappropri-
ate use of opioids by some patients. This variation occurred 
despite only subtle and inconsistent differences across sites 
in mean preoperative WOMAC Pain and Function scores as 
well as minimal variation in depressive symptom and pain 
catastrophizing scores (Table 5). While some of these differ-
ences were statistically significant, these small differences, in 
our view, are not clinically important. These data suggest that 
between-site differences in pain, function, and psychological 
distress likely did not contribute to variation in opioid use. 
Given the lack of benefit of opioids over and above that of 
NSAIDs,8,9 combined with risks associated with persistent 
opioid use,7 we suspect that opioid overuse is more common 
and more consequential than opioid underuse in this popu-
lation, but more research is needed to test this hypothesis.
Site-specific differences in opioid use rates may be related to 
a variety of factors including variations at the person-level (eg., 
age and sex),43 hospital system level,43 physician group practice, 
and state-to-state differences across sites.44 The institutional 
culture of Site 1, for example, may have been more lenient 
or more prone toward opioid use as compared to that of Site 
4 regarding opioid use among these types of patients. While 
our study was not designed or powered to identify factors that 
explained this variation, these site-related differences provide 
impetus for studies of geographically based variation in opioids 
prescribed in KA with a focus on identification of patient-, 
clinician-, and system-level factors influencing opioid use.
Our study has several additional key findings. Contrary 
to our hypothesis, the prevalence of opioid use was not 
higher in our sample of patients with moderate to high pain 
catastrophizing as compared to heterogeneous samples 
of patients undergoing KA.3,17,18 Given that patients who 
catastrophize are psychologically distressed and feel hopeless 
about their pain, it is encouraging that higher opioid use was 
not seen in our sample as compared to more heterogeneous 
KA cohorts. The OME also was relatively low across the 
four sites and suggests that high-dose opioid use is relatively 
uncommon in this population.
Prior evidence on patients scheduled for KA did not specify 
details of opioid type and dose or the extent of variation across 
sites or geographic regions. Pain in other areas of the body 
is common in KA,45,46 and current evidence also does not 
characterize whether opioids were used for knee pain versus 
other bodily pain. In addition, only one study reported OME,3 
an indicator of opioid dose and a predictor of persistent use.3,22
Our hypothesis regarding patient-level, modifiable 
risk factors of opioid use and dosage was not supported. 
Table 5 Preoperative WOMAC, PHQ-8, and PCS scores stratified by site
Site 1, mean (SD) Site 2, mean (SD) Site 3, mean (SD) Site 4, mean (SD)
WOMAC Pain* 12.4 (3.3) 10.3 (3.2) 11.4 (3.5) 11.5 (3.3)
WOMAC Function* 37.8 (11.3) 32.7 (11.9) 39.0 (11.1) 38.8 (10.9)
PHQ-8 6.8 (5.0) 4.6 (3.9) 6.3 (5.4) 5.9 (5.0)
Pain catastrophizing* 31.6 (9.1) 26.7 (8.6) 30.8 (9.7) 30.5 (9.1)
Note: *P < 0.01 using analysis of variance with correction for multiple comparisons.
Abbreviations: WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; PHQ-8, Patient Health Questionnaire-8; PCS, Pain Catastrophizing Scale.
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 Potentially modifiable psychological distress variables, 
number of bodily pain sites, and WOMAC Pain scores were 
not associated with either opioid use or dosage. Identification 
of variables and particularly modifiable variables associated 
with opioid use or dose prior to KA may facilitate the 
development and testing of interventions to reduce opioid use 
prior to KA and subsequently reduce persistent opioid risks 
and improve outcomes. Given that KA surgery is effective 
at substantially reducing knee pain in ~80% of patients,47 
persistent opioid use following KA should be uncommon. 
Goesling et al3 reported that ~15% of KA patients were taking 
opioids 6 months following surgery, and of these patients, 
two-thirds were taking opioids prior to surgery. KA appears 
to provide a window of opportunity for reduction of persistent 
opioid usage. Interventions designed to reduce opioid use 
appear to have strong potential,4 although more research is 
needed to inform these approaches.
In our study, preoperative opioid use was independently 
associated with younger age, African-American race, higher 
comorbidity scores, and higher self-efficacy. Patients with 
higher self-efficacy scores reported having more control of 
their OA symptoms and also were more likely to use opioids. 
Higher opioid use among those with higher self-efficacy 
may be driven, at least somewhat, by patients who express 
confidence in their ability to control their pain via opioids, 
although more research is needed to test this hypothesis.
While we were unable to identify modifiable factors 
associated with opioid use, clinicians may benefit from rec-
ognizing which patients may be at greater risk for opioid use, 
such as those who are African American and younger and 
those with multiple comorbidities. Raising clinician aware-
ness of the demographic subgroups at risk for opioid use may 
reduce overprescribing to these subgroups. The challenges, 
particularly among these higher use subgroups, are to identify 
patients in whom benefits from opioid use outweigh risks 
and patients most likely to be at risk for persistent opioid use 
when risks may outweigh the benefits of opioid treatment and 
to determine the optimal protocol each patient should use.
The only variable associated with opioid dose, as mea-
sured by OME, was lower depressive symptom scores. This 
was an unexpected finding and, to our knowledge, has not 
been reported previously. Patients with lower levels of depres-
sive symptoms may advocate for higher doses of opioids or 
clinicians may be sensitive to people with higher levels of 
depressive symptoms and are less likely to prescribe higher 
doses to these patients. Alternatively, pain control afforded 
by opioids may impact depressive symptoms in a positive 
way. More research is needed to corroborate and further 
explore these findings.
Our study had a number of strengths and limitations. The 
major limitation was our cross-sectional study design, but, to 
our knowledge, ours is the first to report site-specific variation 
in opioid use among patients scheduled for KA. Additionally, 
while the study sites were located in the southern and north-
east US, our study does not inform the extent of variation in 
opioid use in other parts of the US. Our study also examined 
only university-based practice settings. Future work should 
examine opioid use variation in more geographic areas and 
other practice settings, similar to the work of McDonald 
et al.42 A strength of our study is that it is the first to report 
opioid use specifically for knee pain. However, because we 
did not collect opioid use data for other pain sources and 
locations, our estimates may underestimate overall opioid 
use. Additionally, although we relied on a combination of 
self-report and medical record review to confirm opioid use, 
dosage, and frequency, we did not perform urinary biomarker 
analysis to confirm usage. Finally, we recruited people with 
moderate to high levels of pain catastrophizing. Results may 
not generalize to people with either no pain catastrophizing 
or low levels of pain catastrophizing.
Conclusion
People who catastrophize about their pain prior to KA did not 
demonstrate significantly increased opioid use compared with 
estimates from heterogeneous KA samples previously studied. 
However, variation in the prevalence of opioid use across study 
sites was substantial. Patients at a greater risk of preoperative 
opioid use had a higher comorbidity burden, were younger, 
and more likely to be African American. While opioid dos-
age was relatively low, the prevalence of preoperative opioid 
use was relatively high, providing the opportunity to develop 
strategies to lower preoperative opioid use in this population. 
Future research exploring the appropriate use of opioids in 
patients with pain catastrophizing before KA is needed.
Significance
Patients who catastrophize about their pain prior to KA dem-
onstrate opioid use rates that are similar to those of people 
undergoing KA in heterogeneous samples. Variation in opioid 
use rates is highly dependent on clinical site.
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